Volume : 11, Issue : 12, December – 2024
Title:
FORMULATION AND EVALUATION OF LIQUISOLID COMPACT FOR ENHANCING DISSOLUTION PROPERTIES OF ATAZANAVIR
Authors :
N.Ravi Kiran, T.Ram Chander
Abstract :
To improve oral delivery of the BCS class II medication atazanavir, a special liquisolid powder compact (LSPCs), formulation was created. In the solubility tests, span 20, span 80, propylene glycol, and transcutol HP were employed. Because it is a non-volatile solvent, transcutol HP was utilised in the LSPC formulation. Propylene glycol was used to manufacture Atazanavir LSPCs at the ideal drug concentration, resulting in a high dissolving profile and excellent tablet properties. Using Fourier transform infrared spectroscopy (FTIR) revealed no drug-polymer interactions.
Keywords: Atazanavir, liquisolid compact, Transcutol, FTIR, drug release.
Cite This Article:
Please cite this article in press T.Ram Chander et al Formulation And Evaluation Of Liquisolid Compact For Enhancing Dissolution Properties Of Atazanavir.,Indo Am. J. P. Sci, 2024; 11 (12).
Number of Downloads : 10
References:
1. Alonzo D.E., Zhang G.G., Zhou D., Gao Y., Taylor L.S. Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm. Res. 2010; 27:608–618.
2. Avachat A.M., Parpani S.S. Formulation and development of bicontinuous nanostructured liquid crystalline particles of efavirenz. Colloids Surf., B. 2015;126:87–97.
3. Burra S., Yamsani M., Vobalaboina V. The liquisolid technique: an overview. Brazil. J. Pharm. Sci. 2011; 47:475–482.
4. Chella N., Narra N., Rama Rao T. Preparation and characterization of liquisolid compacts for improved dissolution of telmisartan. J. Drug Delivery. 2014; 2014:1–10.
5. Chella N., Shastri N., Tadikonda R.R. Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan. Acta Pharm. Sin. B. 2012; 2:502–508.
6. Chiappetta D.A., Hocht C., Taira C., Sosnik A. Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability. Nanodrug. 2010; 5:11–23.
7. Crowley M.M., Zhang F., Repka M.A., Thumma S., Upadhye S.B., Kumar Battu S., McGinity J.W., Martin C. Pharmaceutical applications of hot-melt extrusion: part I. Drug Dev. Ind. Pharm. 2007;33:909–926.
8. Elkordy A.A., Tan X.N., Essa E.A. Spironolactone release from liquisolid formulations prepared with Capryol™ 90, Solutol® HS-15 and Kollicoat® SR 30 D as non-volatile liquid vehicles. Eur. J. Pharm. Biopharm. 2013; 83:203–223.
9. Fabbiani M., Di Giambenedetto S., Bracciale L., Bacarelli A., Ragazzoni E., Cauda R., Navarra P., De Luca A. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J. Antimicrob. Chemother. 2009; 64:109–117.
10. Fahmy R.H., Kassem M.A. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: in vitro and in vivo evaluation. Eur. J. Pharm. Biopharm. 2008; 69:993–1003.
11. Friedland G., Khoo S., Jack C., Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J. Antimicrob. Chemother. 2006; 58:1299–1302.
12. Hentzschel C., Alnaief M., Smirnova I., Sakmann A., Leopold C. Enhancement of griseofulvin release from liquisolid compacts. Eur. J. Pharm. Biopharm. 2012; 80:130–135.
13. Javadzadeh Y., Jafari-Navimipour B., Nokhodchi A. Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine) Int. J. Pharm. 2007;341:26–34.
14. Javadzadeh Y., Shariati H., Movahhed-Danesh E., Nokhodchi A. Effect of some commercial grades of microcrystalline cellulose on flowability, compressibility, and dissolution profile of piroxicam liquisolid compacts. Drug Dev. Ind. Pharm. 2009; 35:243–251.
15. Nokhodchi A., Javadzadeh Y., Siahi-Shadbad M.R., Barzegar-Jalali M. The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts. J. Pharm. Pharm. Sci. 2005; 8:18–25.